Overview
DPP-4 inhibitors brand names can be confusing because one diabetes medicine may appear as a generic name, a trademark, or part of a combination pill. The key is to identify the active ingredient first, then check whether the product contains one drug or two. This helps reduce duplicate therapy, improves medication reconciliation, and gives you better questions for your prescriber or pharmacist.
DPP-4 inhibitors are oral, non-insulin medicines used in type 2 diabetes care. They are also called gliptins because many generic names end in “-gliptin.” Common examples include sitagliptin, saxagliptin, linagliptin, and alogliptin. Some products combine a gliptin with metformin or another non-insulin diabetes medicine.
For broader context, you can browse the Type 2 Diabetes article category or the Type 2 Diabetes medical-condition collection. CanadianInsulin.com is a prescription referral platform; when prescription details need confirmation, that step is handled with the prescriber before eligible fulfilment.
Key Takeaways
- Check the generic: The active ingredient is the most reliable identifier.
- Watch for combos: One brand may contain two diabetes medicines.
- Know the suffix: Many DPP-4 inhibitors end in “-gliptin.”
- Confirm the country: Brand names may differ across markets.
- Ask before changing: Do not stop or switch medicines without clinical guidance.
How DPP-4 Inhibitors Work and Why Names Matter
DPP-4 inhibitors work by affecting incretin hormones, which help regulate blood sugar after meals. DPP-4 stands for dipeptidyl peptidase-4, an enzyme that breaks down these hormones. By inhibiting that enzyme, gliptins can support glucose-dependent insulin release and reduce glucagon when blood glucose is elevated.
Why this matters for names is practical. A medication list may show “Januvia” in one place and “sitagliptin” in another. Those are not two separate DPP-4 inhibitors; one is the brand name and the other is the active ingredient. The same issue can occur with other products, including Tradjenta, Onglyza, and Nesina.
Why it matters: A duplicate ingredient can be missed when one entry uses a trademark and another uses a generic name.
The class is generally considered to have a low risk of hypoglycemia (low blood sugar) when used alone. That risk can rise when a DPP-4 inhibitor is combined with insulin or a sulfonylurea. Product labels also discuss other cautions, including pancreatitis warnings, hypersensitivity reactions, joint pain reports, kidney-function considerations for some agents, and heart-failure warnings for certain medicines. The exact wording depends on the product and regulator.
DPP-4 Inhibitors Brand Names and Generic Names
The most common DPP-4 inhibitors brand names are listed below with their generic active ingredients. This table is a quick translation tool, not a complete worldwide directory. Always compare it with the exact label, carton, or pharmacy record you have in front of you.
| Generic Active Ingredient | Example Brand Name | Practical Note |
|---|---|---|
| sitagliptin | Januvia | Also appears in sitagliptin combination products. |
| saxagliptin | Onglyza | Some labels include specific heart-failure cautions. |
| linagliptin | Tradjenta | May be listed as linagliptin in medication records. |
| alogliptin | Nesina | Brand naming may vary by country. |
| vildagliptin | Galvus | Availability and branding vary by jurisdiction. |
| teneligliptin | Tenelia | Seen in some markets, not all formularies. |
| gemigliptin | Zemiglo | Regional availability differs. |
| anagliptin | Suiny | Not a common listing in every country. |
When you review DPP-4 inhibitors brand names, write both names together. For example, list “sitagliptin (Januvia)” rather than only “Januvia.” If the medicine is a combination tablet, record both active ingredients and the release type if the label includes it, such as extended-release.
Brand names can also have look-alike or sound-alike issues. A name may feel familiar but belong to a different diabetes class. For example, Farxiga is not a DPP-4 inhibitor; it is an SGLT2 inhibitor. If you are comparing class names, this overview of SGLT2 Inhibitors Drugs can help separate the naming patterns.
Combination Products That Include a DPP-4 Inhibitor
Combination products contain two active ingredients in one tablet, so the brand name alone is not enough. Many DPP-4 inhibitor combinations pair a gliptin with metformin. Others pair a gliptin with a medicine from another class, such as an SGLT2 inhibitor or a thiazolidinedione.
| Combination Brand | Active Ingredients | What to Check |
|---|---|---|
| Janumet | sitagliptin + metformin | Check whether metformin is also listed separately. |
| Janumet XR | sitagliptin + metformin extended-release | Confirm the release type on the label. |
| Kombiglyze XR | saxagliptin + metformin extended-release | Review both components during medication reconciliation. |
| Jentadueto | linagliptin + metformin | Record both names, not only the trademark. |
| Kazano | alogliptin + metformin | Confirm the active ingredients by label. |
| Oseni | alogliptin + pioglitazone | Ask which monitoring applies to each component. |
| Qtern | saxagliptin + dapagliflozin | This combines DPP-4 and SGLT2 classes. |
| Steglujan | sitagliptin + ertugliflozin | This also combines DPP-4 and SGLT2 classes. |
Combination products can simplify a medication schedule, but they can also hide overlap. A person might have a DPP-4 inhibitor listed as a standalone tablet and then receive a combo pill that contains the same gliptin. That is the kind of duplication a pharmacist or clinician will look for during medication reconciliation.
If your list includes Janumet or an extended-release version, the Janumet XR product page can help you recognize the product family while you still confirm details against your own prescription label. For a broader comparison of weight-related questions, see Does Janumet Cause Weight Loss.
How to Read Your Label Without Guessing
The safest way to interpret dpp-4 inhibitors brand names is to read the active ingredient line first. On many labels, the trademark appears prominently, while the generic name appears nearby in smaller text. The active ingredient is the part clinicians use to detect duplicate therapy, interactions, and class overlap.
- Start with the generic: Find the active ingredient line.
- Count the ingredients: Look for one name or two names.
- Check the class: Identify whether “-gliptin” appears.
- Compare your list: Match each ingredient across all medicines.
- Note conditions: Kidney disease, liver disease, and heart failure history can matter.
- Bring packaging: Bottles and cartons often clarify unclear names.
Quick tip: Keep a photo of each current medication label on your phone.
Label review is especially important after hospital discharge, specialist visits, or pharmacy changes. Medication lists often carry old entries forward. They may also use different naming conventions, such as “DPP4 inhibitor,” “DPP 4 inhibitor,” or “gliptin.” These usually refer to the same class, but the active ingredient still needs confirmation.
Do not assume that a lower-cost or cash-pay alternative is automatically equivalent. Some patients explore cash-pay options or cross-border fulfilment depending on eligibility and jurisdiction, but the clinical question remains the same: which active ingredient and formulation did your prescriber intend? A pharmacist can also explain whether a product is a single-ingredient tablet, a fixed-dose combination, or a different class entirely.
Safety Labels, Side Effects, and Monitoring Terms
DPP-4 inhibitor labels include safety topics that are worth recognizing, even if you are not making treatment decisions yourself. Common label themes include low blood sugar risk when combined with certain other medicines, pancreatitis warnings, serious allergic reactions, severe joint pain reports, and kidney-function considerations. Some agents also carry heart-failure-related warnings.
Seek urgent medical help for symptoms that could suggest a severe allergic reaction, such as swelling of the face, lips, tongue, or throat, trouble breathing, or widespread rash. Severe abdominal pain that does not go away also needs prompt medical review, especially if it is associated with vomiting or feeling very unwell. These symptoms do not prove a medicine caused the problem, but they should not be ignored.
Monitoring terms can feel technical. “Renal function” refers to kidney function. “Hepatic impairment” refers to liver-function concerns. “Hypersensitivity” means an allergic-type reaction. If one DPP-4 inhibitor is changed to another, it is reasonable to ask which active ingredient changed and whether any monitoring plan changed with it.
Weight questions also come up often. DPP-4 inhibitors are not usually discussed as weight-loss medicines, but individual experiences vary and treatment plans may include other drugs that affect weight. For more context, see DPP-4 Inhibitors Weight Loss and Januvia and Weight Loss.
How DPP-4 Inhibitors Compare With Nearby Diabetes Classes
DPP-4 inhibitors are one group within non-insulin type 2 diabetes medicines. They are different from SGLT2 inhibitors, GLP-1 receptor agonists, metformin, sulfonylureas, and insulin. The differences matter because each class has different dosing formats, side-effect profiles, monitoring needs, and clinical reasons for use.
Farxiga is a common source of confusion because it appears in diabetes medicine discussions, but it is not a gliptin. Farxiga is the brand name for dapagliflozin, an SGLT2 inhibitor. Qtern, however, combines saxagliptin, a DPP-4 inhibitor, with dapagliflozin, an SGLT2 inhibitor. That is why combination pills require ingredient-by-ingredient review.
Ozempic is another common comparison point. Ozempic is not a DPP-4 inhibitor or a gliptin. It belongs to the GLP-1 receptor agonist class. DPP-4 inhibitors and GLP-1 receptor agonists both relate to incretin biology, but they are not the same type of medicine. If your medication list contains more than one diabetes class, ask your clinician or pharmacist to explain the purpose of each one.
For more class-level background, you can read SGLT2 Inhibitors Explained. You can also browse the broader Diabetes product category for navigation across diabetes-related items without treating the category as medical advice.
Questions to Bring to Your Clinician or Pharmacist
A short question list can turn a confusing medication review into a focused conversation. Bring the bottle, the prescription label, and any hospital or specialist medication list. If the names do not match, ask the pharmacy to compare the active ingredients rather than relying on trademarks alone.
- Which ingredient changed? Ask whether the generic name changed.
- Is this a combo? Confirm whether two drugs are in one tablet.
- Any duplicate ingredient? Compare against your full medicine list.
- What monitoring applies? Ask about kidney, liver, or heart-related checks.
- What symptoms matter? Review when to seek urgent care.
- Which names should I record? Keep brand, generic, and directions together.
This is also the right moment to ask about affordability or coverage constraints. “Cheaper alternative” is not one clinical decision. It may involve insurance formularies, generic availability, country-specific brands, combination versus separate tablets, and whether the alternative is appropriate for your health history. Do not substitute a product based only on cost or name similarity.
Authoritative Sources
For the most reliable details, use official labels, regulator databases, and major clinical guidance. These sources can help verify approved product names, active ingredients, and safety wording for a specific country.
- Search Health Canada’s Drug Product Database
- Use the FDA Drugs@FDA label database
- Review Diabetes Canada clinical practice guidelines
Use this page as a name-matching aid, then confirm your exact product with the prescription label, pharmacist record, or prescriber. DPP-4 inhibitors brand names are useful shortcuts, but active ingredients are the safer reference point for real medication lists.
This content is for informational purposes only and is not a substitute for professional medical advice.
